BACKGROUND: Whileincreasesinprescriptiondrugspending have moderated in recentyears,drugspending is still aconcern among managed careorganizations and healthplanadministrators .Inorder to minimize costincreasesfromyeartoyear, many healthcare plans have shiftedmoreofthe costofmedications to themember-consumer. Coinsurance,abenefitdesign in which thepatient pays apercentage of thecostofthe medication, is garnering more attentionasatypeof cost-sharing that differsfromthe traditionalcopaymentmodel.
RESULTS:Beneficiaries in theinterventiongroup paid31.8% of total pharmacybenefit cost at thepoint of care versus 31.5%inthe comparison group in thepost-changeperiod. Theincreasesinbeneficiary costfromthe pre-changeperiodtothe post-changeperiodwerenot significantlydifferentfor theintervention(7.5%)and comparison (3.0%) groups(P =0.983). From thepre-changeperiodtothe post-changeperiod, total spending per memberincreased $4.57PMPM(6.3%), from$72.29to$76.87inthe intervention group versus a$5.87 PMPM increase (9.5%),from$61.54 to $67.41,inthe comparison group,arelativedifference of $1.30PMPM ( P =0.013). Theincreasesinutilization fromthe pre-changeperiodtothe post-changeperiodwerenot significantlydifferent in theintervention group (2.4%) versus thecomparisongroup (4.6%, P =0.189). Utilization per patient in the3essential drug classes increased4.1%(1.59 days PPPM)in theinterventiongroup versus 9.0%(3.23 days PPPM)inthe comparison group ( P =0.004). Totalexpenditures in the3classes forthe intervention and comparison groupsincreased 8.2% ($5.07 PPPM)and 13.3%($7.80 PPPM), respectively, adifference of $2.73PPPM ( P =0.003). Beneficiary costfor all3drugclasses increased$2.20 PPPM (9.2%) in theintervention group versus $2.12PPPM (9.1%) in thecomparisongroup ( P =0.032). The increases in employer costfor the3essential drug classes in theintervention group (7.5%, $2.86PPPM)and comparison group (16.1%,$5.67PPPM) didnot significantlydiffer(P =0.057).
CONCLUSIONS:Apharmacybenefit design changefromtiered copayment to tiered coinsurance,withoutasignificant increase in beneficiary OOP costs,was associated with alower rate o fincrease in total pharmacy benefitcostand no significantreduction in utilization.For utilizers in 3essential drug classes,drugutilization and totalspending increasedin thecoinsurance group butatalower rate of increase compared with the copaymentgroup.The coinsurance design provides anotherapproach for controlling prescriptionutilization and spendingfor certainmedication classes.
•P reviousresearchonthe effect of coinsurancehas yieldedmixed resultsa nd has been limited to only af ew services ands elect populations; e.g.,e lderly,l ower income,o rp atientsf or whom out-of-pocketc ost wasv eryl ow before coinsurancei mplementation.
•T he effect on prescription drug utilization of changing from a tiered copaymenttoatieredcoinsurance structure has notbeen examined.
•F ollowing implementationo fa25%c oinsurance structure (and 50%f or non-preferredt ier-3d rugs)w ithm inimuma nd maximumout-of-pocketcostsfor each of 4tiers,total prescription drug spending increased by 6.3%, compared with a9 .5% increasefor acomparison plan thatretaineda3-tiercopayment structure ( P = 0.013).
•T he switchf rom3 -tierc opayment to coinsurancew as associated with a2.4%increaseinper memberutilization thatwas not different from the4.6%increaseinutilization in thecomparison group( P = 0.189),a nd the7 .5%i ncreasei nb eneficiary cost in thecoinsurance groupwas notdifferentfromthe 3.0% increase in thecomparison group(P = 0.983). Theriseinspendingisdrivenbyaninfluxofnew,expensive medications, drug pricei nflation,a nd increasedu tilization of prescription drugs. Of thesefactors,increased utilization may be most easily influencedbyhealth plansand pharmacy benefit managers. 3 Patientc ost-sharing throughacopaymento rc oinsurance is onecommontechnique forinfluencing patientutilization of medications.Previousresearchinthisareahas shownthatincreasing patientc ost-share decreasesm edicationu se. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] However, only a fewo ft hese studiesu tilizeds trongr esearchd esigns,s ucha sa pre-post intervention design with ac omparatorg roup. [6] [7] [8] 14, 16, 17, 19 Also,few studiesexamine thechanges seen in larger cost-sharing differencesinanadult,commercialinsurance population. 8, 14 Thechallenge when increasing patientcost-share is to ensure that patients do notf orgo valuable treatments as ar esulto f theg reater cost-share.R esearchh as shownt hat2 -tier benefit designs, usedt oi nfluence thec hoice of treatmenti nf avor of lower-cost genericmedications,decreased drug expenditures and utilization over single-tierprogramsbut still didnot differentiate betweenmoreand less valuable brandnametreatments. 22 Studies examiningfurther differentiation have shownthatm ovingfrom a2-tier (generic andbrand)toa3-tier (generic,preferred brand, non-preferredb rand)c opayment system decreasest he use of non-preferredb rand medications andi ncreases theu se of preferred brandmedications andgeneric medications. 3, 8, 14, [23] [24] [25] [26] [27] [28] Most pharmacy benefit design studiestodatehave examined therelationshipbetween changestoflatcopaymentsand utilization of medications.C oinsurance benefitsa re becoming more widely used, andt here is little information about thee ffect that atransitionfromfixed-dollarcopaymentstocoinsurance hason prescription drug utilization.C oinsurance reflectsd ifferences in thec ostso ft he medicationst of urther differentiate products within each tier.I na ddition, thec ost paid by thec onsumer adjustsa sd rugp ricesi ncrease, stabilizingt he cost-share mix betweenthe consumer andpayerovertime.
Research on coinsurancei sl imited andh as yieldedm ixed results. Studiesw erec onductedf ollowing ac ost-sharing change from $0 or $2 copayments perp rescriptiont o2 5% coinsurance (including monthlya nd annual maximumo ut-of-pocket [OOP] expense) implemented in Quebec,C anada. Investigators found that utilization in certaindrugclasses remained unchanged, 13, 29, 30 whileu tilization decreasedi no thers. 13, 15 However, theses tudies arelimited in theirrelevance to more recentcost-sharing changes, whereb aselinep atient expenditures areu suallyh igher. Some studiesh ave compared thee ffectso fi ncreased copayments and increasedcoinsurance ratesondrugutilization andmedical care utilization in elderly populationsi nt he United States andh ave foundad ecreaseinexpendituresand utilization with no subsequentchangeinmedical expenses. 16, 17 More recentresearchintocoinsurance hasexaminedthe effect of coinsuranceo ns elf-monitoring of blood glucoseb yd iabetic patients andonadherence ratestobeta-blockertherapy. 31, 32 In the studyo fd iabeticp atients, dailyu tilization of glucosem onitoringt ests tripsd eclined afterthe plan switchedfromn om ember cost-sharing to coinsurance, butt he amount of change wasn ot clinically significant. 31 Theb eta-blocker studye xaminedt he effect of OOPc ost-sharing changes, firstf rom$ 0t o$ 10 or $25 copaymenta nd then to 25%c oinsurance.C ost-sharing changes were associated with minimal(approximately 1%)declinesinthe beta-blocker adherencerate(percentage of patients with medication possessionr atio >80%)f or patients with hypertension and no significantc hangei nt he rate of initiation of beta-blocker therapyf ollowing am yocardiali nfarction.
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Earlierc oinsurance researchwas conductedbeforethe development of expensivebiologicmedications andthe introduction of genericdrugs in several blockbusterdrugclasses.
To date,nostudies have examined theeffect of changing from at iered copaymentd esignt oatiered coinsuranced esign. With little evidence on theeffect thatthistypeofchangewill have on patientb ehavior andc osts, we examined such ad esignc hange andi ts effectso ne xpendituresa nd utilization.B yu sing ac omparisong roup to adjust foru tilization andc ost trends in ap lan with ac opayment design,t hiss tudy wasa blet oe stimatet he impact of thebenefit design change on medication utilization and expenditures.Utilization wasanalyzedbothoverall (for alltherapeutic classesc ombined) andf or 3c hronic medicationc lasses: antihypertensives,antidepressants,and statins.
■■ Methods

StudyPopulation
This retrospectivec ohort studya nalyzede nrollmenta nd pharmacy claimsd atam aintainedb yamanagedc areo rganizationi nam idwesterns tate from September1 ,2 004, throughMarch 31, 2006 . It wasapproved by theinstitutional review boarda tt he Universityo fN ebraskaM edical Center. Thes tudy usedap re-post analysis of an intervention group evaluateda gainst ac omparison group. Both thei ntervention
•F or patients whou sedd rugs in 3e ssentiald rugc lasses (antihypertensives, antidepressants,a nd statins) in thep re-change andpost-changeperiods,total pharmacy benefit cost increased by 8.2%inthe coinsurancegroup and13.3% in thecomparison group, ad ifference of $2.73p er patientp er month ( P = 0.003). Thei ncreasei nu tilization fort he 3e ssentiald rugc lasses was lower in theintervention group( 4.1%)thaninthe comparison group( 9.0%, P = 0.004).
Effect on Drug Utilization andExpendituresofa Cost-ShareChange F romCopaymenttoCoinsurance andc omparison cohortsr epresentedl arge privatelyi nsured preferredp rovider organization groups.B othc ohorts employed an identical3 -tier copaymentp harmacyb enefit plan design (generic,formulary brand, non-formularybrand) during thepre-implementationperiod. On September 1, 2005, thei ntervention groupc hanged from the3 -tierc opayment design to a4 -tier coinsuranced esignd ue to an employer groupdecision. Table1showsthe groups'benefit during each period of analysis.A4thc ost-share tier (25%)w as created in thei nterventiong roup fors pecialty pharmaceuticals, includingi njectable medications, whichw eret ier-2 or tier-3 copaymentm edications during thep re-changep erioda nd remained in thesec opayment tiersf or thec omparison group throughout thestudy period.Aseparate studyevaluatingthe effect of theb enefit change on thosem edications is underway. 33 Thef ormulary andtier status forall otherm edications (Table 2 ) wasconsistentbetween the2study groups.
Both planso ffered an optional mail orderb enefit.M ember cost-share at mail fora6-month supply( 151to1 80 days supply) wase quivalentt o5c opaymentsf or that tier forthe comparison groupand thecorrespondingcoinsurance rate forthe respective tier forthe intervention groupwithminimum/maximum values 5times the1 -month supply values.For example, ageneric medication filled at mail orderf or a1 80 days supplyinthe intervention groupwould be subject to 25%coinsurance with aminimum of $25( 5t imes thet ier-1 minimumo f$ 5) andam aximum of $125 (5 timesthe tier-1 maximumo f$ 25). Claimsp rocessed at communitypharmaciescould be filled only for3-month supplies or less.Mailorder utilization ratesfor theintervention andcomparisong roupsd uringt he entire studyp eriodw ere0 .84% and 0.11%ofclaims, respectively.
An importantf eature of thec oinsurance design wast he inclusionofminimum andmaximum patientcost-sharing levels. Them inimum valuew as included to maintain thec ost-share differences betweent iers andt he maximumw as included to insulate them emberfromthe cost of relatively expensivem edications. Patientsinthe intervention groupc ould seeareduction in theirspendingontier-1 medicationsbecause the$5minimum wasbelow theirprevious$ 10 copayment. Fortier-2 medications, anychangeinpatient cost-share wasrelated to medication price because them inimum wase qual to the$ 25 copayment. Users of tier-3 medications, however, facedam inimum increase of $10b ecause them inimum ($50)w as greatert hant he previous copayment.
To be included in thep resent study, beneficiaries hadt ob e continuously enrolled fort he entire 19-month studyp eriod (12m onthsbeforethe plan change and7m onthsafter thep lan change)a nd be ≥ 18 years of agea tt he beginningo ft he study period.All beneficiaries meetingthe continuous enrollmentc riteriaw erei ncludedi na nalyseso fo verall (all drugs) utilization andcost.Tobeincludedinthe analyses of the3essentialmedica-tion classes( antihypertensives, antidepressants,a nd statins),a n PharmacyB enefit Designs 
Definition of EssentialDrugClasses
Drug classesfor theanalysesofessentialmedications were limited to chronicmedications previously defined as "essential," 15 were not subject to prior authorizationp rograms, andw eren ot typically dispensed"as needed." Themedicationclasses were (1)antihypertensives identified by Medi-Span GenericProduct Identifier (GPI) codesb eginning with 33 (beta-blockers), 34 (calciumc hannel blockers), 36 (angiotensin-convertinge nzymei nhibitors, angiotensin II receptorb lockers, adrenolytica ntihypertensives), and 37 (diuretics); (2)a ntidepressants,w hich were limited to selective serotonin reuptake inhibitors (SSRIs)a nd serotonin/norepinephrine reuptake inhibitors (SNRIs)i dentifiedb yG PI codes beginningw ith5 816, 5818,a nd 58300090;a nd (3)H MG-CoA reductasei nhibitors( statins) ands tatin combinationp roducts identified by GPIcodes beginningwith3940and 3999.
Utilization andExpenditures
Utilization included both communitya nd mail orderp harmacy claims. Employer cost wasd efined as thea mountp aid by theplansponsor;beneficiary cost wasthe amount paid by thepatient; andtotal cost wasthe sumofthe discounted ingredientcost plus thedispensingfee to thepharmacy. Pharmacy claim counts were adjusted ford ayss upply( i.e.,9 0d ays supply =3 claims).
Thea nalysese xamined( 1) utilization andc ost overall( i.e., forall therapeuticclasses),and (2)participation rates, utilization, andc ost forthe 3e ssentialm edicationc lasses. Forthe analyses of overall utilization,t otals( pharmacy claimsc ounts, member OOPcosts, employer costs, andtotal costs) foreachofthe 2study periodsweredivided by thet otal number of enrollmentm onths (6 months foreachmemberbecause thestudy samplewas limited to continuously eligible members) to yieldper memberper month (PMPM) values.Participation ratesfor each of the2periods were calculated as thepercentageofmembers with aclaim foreachof the3essentialmedicationclasses.
Fore acho fthe 3essentialm edicationc lasses, theu tilization measurew as totald ayss upplyd ispensed,a nd cost measures included member OOP, employer cost,and totalcost.For theanalyses of these3classes, dividing totals by thenumberofenrollment months (6 months in each period)yielded perpatient permonth (PPPM)v aluesb ecause thesea nalysesi ncludedo nlym embers with utilization in thetherapeutic classinbothstudy periods.
StatisticalAnalysis
Fort he statisticala nalyseso fu tilization andc ost, two 6-monthc ohortsw erec onstructed fort he intervention and March 31, 2006 , to account for any seasonality that might affect utilization. The first month after the benefit change was excluded to account for hoarding in the intervention group during August previous to the benefit change that would have skewed September 2005 utilization in the intervention group. Changes in utilization and expenditures between the prechange and post-change periods for both groups were calculated. A difference-in-difference (DD) analysis was utilized to determine the difference in the change (pre-to post-) between the intervention and comparison groups. The DD analysis is the most appropriate measure of the effect of the design change because it controls for the utilization (expenditure) changes that would have occurred over time and also for differences between the intervention and comparison groups in utilization. The Wilcoxon rank sum test (also known as the Mann-Whitney U test) was used to analyze the difference in the change between the 2 groups. Two-tailed t tests were used to determine the significance in difference in age between the 2 groups and χ 2 analyses were used to calculate the difference in gender between the 2 groups and the participation rates for the 3 medication classes included in this study. The Wilcoxon rank sum test was used to analyze the difference in Chronic Disease Scores 34 between the 2 groups. The significance level for all statistical analyses was set at P ≤ 0.05. All cohorts were grouped and statistical analyses were conducted with SAS Version 8.0 (SAS Institute Inc., Cary, NC).
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■■ Results Overall Utilization A total of 46,311 and 7,916 members aged ≥ 18 years were continuously enrolled during the study period in the intervention and comparison groups, respectively. Changes in PMPM utilization and cost for the 2 groups are presented in Table 3 . In the post-change period, intervention group beneficiaries paid 31.8% of total prescription drug cost versus 31.5% for comparison group beneficiaries. The increases in beneficiary cost from the pre-change to the post-change period were not significantly different for the intervention (7.5%) and comparison (3.0%) groups (P = 0.983). From the pre-change to the post-change period, total spending per member increased $4.57 PMPM (6.3%), from $72.29 to $76.87, in the intervention group versus a $5.87 PMPM increase (9.5%), from $61.54 to $67.41, in the comparison group, a relative difference of $1.30 PMPM (P = 0.013). The increases in utilization from the pre-change to the post-change period were not significantly different in the intervention group (2.4%) versus the comparison group (4.6%, P = 0.189).
Participation Rates for 3 Essential Drug Classes
Of the 46,311 and 7,916 study members in the intervention and comparison groups, respectively, 13,870 (29.9% of the intervention group) and 2,126 (26.9% of the comparison group) filled at least 1 prescription for a medication in 1 of the 3 study drug classes in the pre-change period. For all 3 classes, participation was higher in the intervention group than in the comparison group in both the pre-change and post-change periods (Table 4) . Participation rates increased slightly from the pre-change to the post-change period in both groups. While the increases were slightly greater in the comparison group than in the intervention group for all 3 classes, the differences in the change amounts were not statistically significant.
Utilizers of 3 Essential Drug Classes
A total of 11,917 members in the intervention group and 1,792 members in the comparison group filled at least 1 prescription for at least 1 of the 3 essential medication classes in both the pre-change and post-change periods. Among users of the 3 essential medication classes, the intervention group was significantly older and sicker than the comparison group. Except in the antidepressant class, the intervention group had a significantly higher percentage of women filling prescriptions than did the comparison group (Table 5) . While these differences are statistically significant due to the large sample 
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size, they are probably not practically or clinically significant. Women were generally the predominant gender in all drug classes in both the intervention and comparison groups with the exception of the statins drug class, where more than half the patients were men. Table 6a shows utilization and expenditures for patients in the 2 study groups in the pre-change and post-change periods. Total PPPM days supply summed across the 3 drug classes increased from the pre-change to the post-change period for both the intervention and comparison groups, from 38.99 to 40.58 (4.1%) for the intervention group and from 35.78 to 39.01 (9.0%) for the comparison group. The change amount was slightly smaller for the intervention group (1.59 days PPPM) than for the comparison group (3.23 days PPPM, P = 0.004). From the pre-change to the post-change period, mean PPPM OOP spending increased by $2.20 and $2.12 for the intervention and comparison groups, respectively, a difference of $0.08 per month (P = 0.032). The increases in employer cost in the intervention group (7.5%, $2.86 PPPM) and comparison group (16.1%, $5.67 PPPM) did not significantly differ (P = 0.057). The PPPM changes in the total cost of prescription drugs were $5.07 (8.2%) and $7.80 (13.3%) in the intervention and comparison groups, respectively, a difference of $2.73 PPPM (P = 0.003). The 2 groups did not significantly differ with respect to change in utilization of tier-1 or tier-2 drugs. For tier-3 drugs, utilization remained essentially constant from the pre-change to the post-change period in the intervention group (change of 0.09 days PPPM) but increased slightly in the comparison group (change of 0.43 days PPPM, P = 0.002).
From the pre-change to the post-change period, patient OOP cost for tier-1 medications decreased by $0.85 PPPM in the intervention group and increased by $0.43 PPPM in the comparison group (P < 0.001). The decrease in patient OOP for the intervention group was offset by an increase in the employer group's expenditures. The increase in employer group expenditures of $1.33 PPPM in the intervention group was significantly higher than the $0.29 increase observed in the comparison group (P < 0.001). As a result, the intervention and comparison groups did not significantly differ with respect to change in total spending on tier-1 medications.
With respect to patient OOP spending, results for tier-2 medications were the opposite of the tier-1 results. PPPM OOP spending increased $0.27 more in the intervention group than in the comparison group (P < 0.001), while PPPM employer group spending increased by $1.43 less in the intervention group than in the comparison group (P = 0.017). As with the tier-1 medications, the 2 study groups did not significantly differ with respect to change in total tier-2 cost (P = 0.150).
PPPM OOP expenditures on tier-3 medications increased by $1.09 more in the intervention group than in the comparison group (P < 0.001). Employer group spending on tier-3 medications decreased by $0.77 PPPM in the intervention group while it increased by $1.65 PPPM in the comparison group (P < 0.001).
As a result, overall spending on tier-3 medications increased by $1.33 more PPPM in the comparison group than in the intervention group. Tables 6b-6d show the differences in utilization and expenditures for the 3 classes of medications. Overall utilization increased in both study groups for the 3 classes evaluated. The increase in utilization was significantly less for the intervention group than for the comparison group in each class. No significant differences in total utilization or cost for tier-1 or tier-2 medications were observed in any class; only utilization of tier-3 antihypertensives (P = 0.031) and tier-3 statins (P = 0.029) differed significantly from the comparison group.
Medication Class Utilization and Expenditures
The effect of the benefit change on OOP spending varied depending on class and tier. Overall OOP expenditure increased $1.54 PPPM less in the intervention group than in the comparison group for antihypertensives (P < 0.001), while it increased $1.90 more in the intervention group than in the comparison group for statins (P < 0.001). For tier-1 antihypertensives and SSRIs/ SNRIs, OOP spending in the intervention group decreased by $1.32 PPPM and $0.07 PPPM, respectively, from the pre-change period to the post-change period. Conversely, OOP spending for tier-3 medications increased significantly more in the intervention group than in the comparison group for all 3 classes. 
Beneficiary Characteristics for Users of 3 Essential Drug Classes
Effect on Drug Utilization and Expenditures of a Cost-Share Change From Copayment to Coinsurance
Mean PPPM Change from Pre-Change Period to Post-Change Period* 
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Employer groupexpendituresincreased forall 3classes inthe comparison group, buttheydecreased forthe SSRIs/SNRIsinthe intervention group. Thea mounto fi ncreasei ne mployers pendingw as higher in thei ntervention group( $2.66P PPM)t hani n thec omparison group( $2.46P PPM)f or antihypertensives but wasl ower fors tatinsi nt he intervention group( $1.61P PPM) thaninthe comparison group($6.62PPPM). Whilethe comparisong roup experiencedi ncreases in employere xpendituresf or tier-3 medications in all classes, employer spending perm onth decreased in theinterventiongroup forall 3classes.
Totalspendingincreased forbothgroupsfor all 3classes,but theincreases in SSRI/SNRIand statin spending were smaller for thei ntervention groupt hanf or thec omparison group. In both of thosec lasses,t he intervention groupe xperienced smaller increasesi ns pendingo nt ier-3m edications than didt he comparisongroup.
■■ Discussion
Ourr esults indicate thatc hangingf roma3 -tier copayment benefit design to a4 -tier coinsuranceb enefit design slowed theg rowtho ft otal PMPM expenditures overall (for all drug classes) andt he growth of PPPM utilization ande xpendituresf or 3c lasses of essentialm edications butd id noth ave asignificantimpacto no verall PMPM utilization.Oursisthe firsts tudy to comparet he effect of ac opayment to coinsurance design change in ap rivatelyi nsured groupa gainst a parallel comparison group. Previous studiese valuated the effect of thec hanget oc oinsurance,a nd showed no change in utilization 13, [29] [30] [31] [32] or ad ecreasei ne ssentialm edicationu tilization. 15 However, theses tudies were conducted with an older population or lowercost-share before intervention.The resultso fo ur studya re consistent with ap reviousp re-post comparatorstudy thatexaminedabenefit change from 2-tier to 3-tier design on prescription drug andm edical utilization andcost. 24 That studydemonstrated increasesinprescription drug utilization aftert he plan change in both thei ntervention andc omparison groups with as lowerr ateo fu tilization growth in theintervention groupand didnot findanincrease in medical servicesutilization.Since ourstudy observed similarp rescriptionu tilization patterns,i tmay be that outcomes were notnegativelyaffected.
Thec oinsurance design implemented during this study maintained thetier system usedinthe typical3-tierc opayment structuref or most drug classes. Thee xception,a sd iscussed previously,i st hata ll biologic medications were movedt oa4 th copaymentt ier.Asw ould be expected forabenefit change that shiftsmorecost to thepatient,the employer groupexpenditures were favorably affected whilet he patiente xperienced as lightly greaterincreaseinOOP spending.
We expected thata dditionalc ost-sharing form oree xpensive medicationsw ould lead to as hift in utilization from them ost expensivecopayment tier (tier 3) to theless expensivetiers (tiers 1a nd 2) as well as as hift to less expensivem edications within each tier.Suchashift should reduce overallmedicationspending relative to afixed-dollarcopayment design.However, we also recognizedthe possibility that patients on tier-3 medications during thepre-changeperiodhad alreadyacceptedahigher OOPcost for theirmedications andtherefore wouldbeless pricesensitive than wouldpatientsusing medicationsinlower tiers.
It is possible that switching behavior forpatientstakingtier-2 andtier-3medications is influenceddirectly by thecost-share of medications thatt heya re currentlyt aking. Patient OOPs pendingf or tier-3 medicationsi ncreased more fort he intervention groupthanfor thecomparison group, whichmay have stabilized utilization in thei nterventiong roup.T he stable utilization of tier-3 medications in thei nterventiong roup compares favorably with thesmall growth in utilization observed in thecomparison group. It is likelythatthe previous 3-tier copaymentdesignhad alreadycausedareductioninthe use of tier-3 medications.One mayalsoexpect thatf ollowing an increase in patientOOP,p lan participants maychoosetodiscontinue use of thosemedications or file claimsw itha nother insurancec arrier if onei sa vailable within theirf amily. Ther ates of discontinuation in filling prescriptions in both groups afterthe intervention date were similar in thata pproximately equal proportionso fp atientsw ithp reperiod utilization were excluded forl acko fp ost-periodu tilization (Figure) .
Fort he antihypertensivem edications,w ithw idelyu sed generics we foundthatpatient OOPdecreased andemployercost increasedaspatientsontier-1 medications experiencedadecrease in theirc ost-sharing;h owever, utilization of tier-1 antihypertensive medications wasnot affected.Thisispromisingfor this class, as Taira et al.found thatgreater compliance wasassociatedwith lowercopayment levels. 35 On theother hand,OOP spending for tier-3 medications increasedmorefor theinterventiongroup than forthe comparison groupand therateoftier-3 utilization growth wascontained.
We didn ot findad ecreasei no verall utilization or expendituresi nt he SSRI/SNRIc lass, butt he rate of growth wasb elow thato ft he comparison group. Goldmane ta l. examined the predictede ffect on SSRI utilization of doubling copayments for privatelyi nsured beneficiaries usingas tatistical model. 10 Their studyp redicted that antidepressantu tilization amongd epressed patients wouldd ecreasea nd utilization of otherm edications wouldd eclinee venm ore. Landsman et al.o bservedag reater discontinuation rate andl ower medication possessionr atio for SSRIsf ollowing thei mplementationo fh igherc ost-sharing levels. 8 Unliket he previous studies, ours tudy wasc onducted at a time wheng enericsw erea vailable fort he SSRI class. Patients on genericm edications experiencedadecrease in patientO OP spending,s ot hatt heyw ould be less likely to discontinue their medications.
Thes tatin medications demonstrated thel argest increase in patiente xpendituresd ue in part to thel acko fw idelyu sed Effect on Drug Utilization andExpenditur es of a Cost-ShareChange From CopaymenttoCoinsurance genericm edications at thetimeo fthis study. Overall utilization of statin medications didnot increase as much in theintervention groupasinthe comparison group. This is consistent with previousestimates by Gibson et al., whof ound thatc ontinuing users of chronicm edications arei nsensitive to pricei nr espondingt o copaymenti ncreases. 5 However, Landsman et al.o bservedt hat followingimplementationofachangefroma2-tierto3-tier benefit,the statin discontinuation rate washigherinthe groupthat changedbenefitsthaninac omparison group. 8 Thediscrepancy betweenLandsmane ta l.'s findingsa nd ourr esults mayb ed ue to differences incost-sharing amounts; Landsman et al.'ssample likelye xperienced larger averagec ost-sharing change thand id oursampled ue to them uchlargeru tilization forf ormulary statinsi no ur plans. As more statinsb ecomea vailable generically andt hose generics become less expensive, it is likelyt hatt he effect of ac oinsurance design implementation will be similart o that seen with thea ntihypertensivem edications in thep resent study.
Theminimum/maximum cost-sharing amount foreachclaim is importanttonote. As mentionedpreviously,the reason forthe minimumistoensuresufficientOOP cost differentiation between generics andpreferred andnon-preferred brandmedications.The maximuml imitsw eres et to maintain thet ieredd ifferentiation andt ol imit them emberc ost-share fore xpensive medications. Thed ecreasei np atient cost-share fort ier-1m edications in the intervention groupcan be attributed to thedifference from a$ 10 copaymentt oc oinsurance with a$ 5m inimum.H owever, providing incentives to thepatient to use generics because they may cost less is aproactive benefit design.Benefit designsthatutilize adifferentminimum/maximumdollarscheduleornominimum/ maximumcapsmay have different resultsw henswitchingfrom copayments to coinsurance.
Ac oinsurance benefit design has potentiala dvantageso vera dollarc opayment design forb othp lans ponsorsa nd beneficiaries.F or plan sponsors, thec oinsurance method of computing memberc ost-share adjustsa utomaticallyt or isingd rugp rices, maintainingt he memberc ost-share at thes pecified proportion (e.g., 20%) over time.Inaddition, thecoinsurance design ensures that them emberi sa ware of thea ctualp rice of thed rug. This awareness of actual priceh as thep otentialt om oree ffectively engage beneficiaries in thecost outcomesofdrugtherapy choices compared with fixed-dollar copayments.H owever,w hile coinsurancee liminates then eedf or theh ealth plan to update the copaymentd ollara mounts over time,t he beneficiary does not know theamounto fthe cost-share untilthe pointo fcarew hen thep harmacyc laim is submitted fora djudicationa nd thec oinsurancepercentageisappliedtothe allowed charge.
Limitations
Therea re severall imitations to ours tudy.F irst,t he study population wass elected from privatelyi nsured groups in 1s tate,a nd theirr esults mayn ot generalize to other populations. Second,o ur studyp opulationc onsisted of patients accustomed to a3-tier copaymentstructure forpharmacy benefits. Theo bservede ffect on patients moving from otherbenefit designsmay be different.Third, medicalclaims were note xaminedt om onitor fora ni ncreaseo rd ecreasei n medicalu tilization or expenditures.S ince we foundo nlya 4.1% increase in utilization of 3e ssentialm edicationc lasses in theinterventiongroup andnosignificantchangeinoverall utilization of alld rugs followingt hisb enefit design change, it is unlikely thata dverse outcomes like thoseo bservedi n Tamblynetal. have occurred. 15 Ourstudy examined 3essen-tialmedicationclasseschoseninpartbecause they represent as ignificantp ortion of thee mployerg roups' medication spending.H owever, in ourP MPMa nalysiso fu tilization for all drug classes, theinterventionand comparison groups did notsignificantlydiffer in theincreaseindrugutilization from thep re-changeperiodtothe post-changeperiod.
Fourth,i ti sp ossiblet hati ncreases to thet ieredc opayment amountsc ould have achieved as imilar outcomewithout implementingc oinsurance,t houghs uchac hangew ould notp rovide some of theother benefitsassociatedwithacoinsurance design. Similarly, it is possible thatac oinsurance structuret hats ignificantly increasedpatient OOPc ostsw ould have produced differentr esults.F inally, furtherr esearchi sn eededt of erreto ut the effectso ft he magnitudeo fc ost-share change from thet ypeo f cost-share change.I nt he presents tudy,t he change from 3-tier copaymentto4-tier coinsuranceresultedinessentiallynochange in thea verage member cost-share,3 1.5% in thep re-change period versus 31.8%i nt he post-changep eriod( Table3 ). The comparison grouph ad very similaro verall member cost-share in both periods, an average of 33.5%i nt he pre-change period versus 31.5%inthe post-changeperiod.
■■ Conclusions
Whilet hiss tudy showed that ac oinsurance design can controlu tilization ands pendingf or certainc lasses of medications,a dditionalq uestions need to be answered about this benefit design.Futureresearchshouldexamine theeffectso f aswitchtocoinsurance on medicalutilization,expenditures, andh ealth outcomes. Additionally, studiest hati nclude a wider rangeofmedicationclasses,including acuteand chronic medications,a re needed.S tudies conductedi np opulations moving from somethingother than a3-tier copaymentdesign ands tudies examiningv arious coinsurancer ates andm inimum/maximumO OP levels aren eededa sw ell. The present studyassessed thes hort-terme ffectso nu tilization andc osts overall (memberand plan sponsor)o fac oinsurance versus a 3-tier copaymentp lan design in whicht he average member cost-share wassimilar forthe 2groups.
Thecopayment to coinsurancebenefit design change explored in this studydid help containthe rise in medication cost trend. Thec oinsurance modelw iths trategicallya ligned minimums 
Effect on Drug Utilization and Expenditures of a Cost-Share Change From Copayment to Coinsurance
may provide an added incentive to use less expensive generic medications, as patient expenditures for tier-1 medications may decrease after the benefit design change. Coinsurance provides an option to employer groups and insurers interested in controlling medication spending without decreasing utilization.
